Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement

Leuk Lymphoma. 2012 Feb;53(2):330-1. doi: 10.3109/10428194.2011.619610. Epub 2011 Oct 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Humans
  • Kidney Failure, Chronic / etiology*
  • Kidney Failure, Chronic / pathology
  • Male
  • Middle Aged
  • Multiple Myeloma / complications
  • Multiple Myeloma / drug therapy*
  • Prognosis
  • Proteinuria / etiology
  • Proteinuria / pathology
  • Pyrazines / therapeutic use*
  • Remission Induction

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Pyrazines
  • Bortezomib